Conflict-of-interest disclosure: A.W.R., M.A.A., T.E.L., and V.S.L. are employees of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to VEN. A.W.R., M.A.A., and T.E.L. are recipients of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research. T.E.L. has received honoraria from AbbVie. R.B. has received sponsorship from AbbVie. S.M.H. has received honoraria from AstraZeneca, Janssen, and Gilead, and nonfinancial assistance from AbbVie. P.M. has served on advisory boards for, and received honoraria or speaker fees from, AbbVie, BeiGene, Janssen, AstraZeneca, Astellas, Otsuka, Menarini, and Jazz. S.P.M. has acted as a consultant/advisor for AbbVie, AstraZeneca, BeiGene, Janssen, Gilead, and Roche. A.W. is an advisory board member for AbbVie and AstraZeneca, and has received honoraria from AbbVie, Roche, AstraZeneca, Novartis, and BeiGene. C.S.T. has received honoraria and research funding from AbbVie and Janssen, and received honoraria from BeiGene. A.W.R. received research funding from AbbVie, Genentech, Servier, Janssen, and BeiGene. J.F.S. receives research funding from AbbVie, Genentech, Celgene, and Janssen, and is an advisory board member for, and has received honoraria from, AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis, and Takeda. M.A.A. has received honoraria from AbbVie, Janssen, AstraZeneca, Novartis, Takeda, Kite, and CSL Behring. P.A.T. has received honoraria from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech, Janssen, Lilly, Merck, and Pharmacyclics. The remaining authors declare no competing financial interests.